

CTI BIOPHARMA CORP  
Form SC 13G/A  
February 05, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 4 - EXIT FILING)\***

**CTI BIOPHARMA CORP.**

**(Name of Issuer)**

**Common stock, no par value per share**

**(Title of Class of Securities)**

**12648L106**

**(CUSIP Number)**

**January 1, 2018**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to \*the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 12648L106

Names of reporting persons

1. Baxalta Incorporated

Check the appropriate box if a member of a group (see instructions)

2. (a)  (b)

3. SEC use only

Citizenship or place of organization

4. Delaware

Sole voting power

Number of <sup>5.</sup>  
0  
shares

beneficially Shared voting power

owned by <sup>6.</sup>  
0  
each

reporting <sup>7.</sup> Sole dispositive power  
person

with  
0

Shared dispositive power

8.  
0

Aggregate amount beneficially  
owned by each reporting person

9.  
0

Check if the aggregate amount  
in Row (9) excludes certain  
shares (see instructions)

10.  
..

Percent of class represented by  
amount in Row (9)

11.  
0.0% (1)

Type of reporting person (see  
instructions)

12.  
CO

Percentage of class calculation is based upon the number of shares of issuer's common stock outstanding as of (1) October 30, 2017 as disclosed by the issuer in its quarterly report for the quarter ended September 30, 2017 and filed with the Securities and Exchange Commission on Form 10-Q on November 7, 2017.

CUSIP No. 12648L106

Names of reporting persons

- 1. Baxalta GmbH

Check the appropriate box if a member of a group (see instructions)

- 2. (a)  (b)

- 3. SEC use only

Citizenship or place of organization

- 4. Switzerland

Sole voting power

- 5. 0

Number of shares

- 6. 0

beneficially owned by

each Sole dispositive power

- 7. 0

reporting person

with

Shared dispositive power

8.  
0

Aggregate amount beneficially  
owned by each reporting person

9.  
0

Check if the aggregate amount  
in Row (9) excludes certain  
shares (see instructions)

10.  
..

Percent of class represented by  
amount in Row (9)

11.  
0.0% (1)

Type of reporting person (see  
instructions)

12.  
CO

Percentage of class calculation is based upon the number of shares of issuer's common stock outstanding as of (1)October 30, 2017 as disclosed by the issuer in its quarterly report for the quarter ended September 30, 2017 and filed with the Securities and Exchange Commission on Form 10-Q on November 7, 2017.

CUSIP No. 12648L106

Names of reporting persons

- 1. Shire plc

Check the appropriate box if a member of a group (see instructions)

- 2. (a)  (b)

- 3. SEC use only

Citizenship or place of organization

- 4. Jersey, Channel Islands

Sole voting power

- 5. 0

Number of shares

- 6. 0

beneficially owned by

each Sole dispositive power

- 7. 0

reporting person with

Shared dispositive power

8.  
0

Aggregate amount beneficially  
owned by each reporting person

9.  
0

Check if the aggregate amount  
in Row (9) excludes certain  
shares (see instructions)

10.  
..

Percent of class represented by  
amount in Row (9)

11.  
0.0% (1)

Type of reporting person (see  
instructions)

12.  
CO

Percentage of class calculation is based upon the number of shares of issuer's common stock outstanding as of (1)October 30, 2017 as disclosed by the issuer in its quarterly report for the quarter ended September 30, 2017 and filed with the Securities and Exchange Commission on Form 10-Q on November 7, 2017.

This Amendment No. 4 amends the Schedule 13G originally filed on May 1, 2015, as amended, and is filed by Baxalta Incorporated, Baxalta GmbH and Shire PLC with respect to the shares of the common stock of CTI Biopharma Corp., with principal executive offices at 3101 Western Avenue, Suite 600, Seattle, Washington 98121.

**Item 4. Ownership .**

- (a) Amount beneficially owned : 0 (1)
- (b) Percent of class : 0.0% (2)
- (c) Number of shares as to which the person has :
  - (i) Sole power to vote or to direct the vote: 0
  - (ii) Shared power to vote or to direct the vote: 0 (1)
  - (iii) Sole power to dispose or to direct the disposition of: 0
  - (iv) Shared power to dispose or to direct the disposition of: 0 (1)

---

(1) The reported securities were beneficially owned by Baxalta GmbH, an indirect wholly-owned subsidiary of Baxalta Incorporated (“Baxalta”), which, in turn, is an indirect wholly-owned subsidiary of Shire plc (“Shire”), following consummation of Shire’s acquisition of Baxalta pursuant to the merger of a wholly-owned subsidiary of Shire with and into Baxalta, which merger transaction closed on June 3, 2016.

(2) Percentage of class calculation is based upon the number of shares of issuer’s common stock outstanding as of October 30, 2017 as disclosed by the issuer in its quarterly report for the quarter ended September 30, 2017 and filed with the Securities and Exchange Commission on Form 10-Q on November 7, 2017.

**Exhibits:**

Exhibit 1 – Joint Filing Statement

Exhibit 2 – Power of Attorney (incorporated by reference to Schedule 13G filed with the Securities and Exchange Commission on February 12, 2016 (File No. 005-48459))

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 5, 2018

BAXALTA  
INCORPORATED

By: /s/ Jeffrey Prowda  
Name: Jeffrey Prowda  
Title: Assistant Secretary

BAXALTA GMBH

By: /s/ Yvo Aebli  
Name: Yvo Aebli  
Title: Director

SHIRE PLC

By: /s/ W R Mordan  
Name: Bill Mordan  
Title: Company Secretary